142 related articles for article (PubMed ID: 29669181)
21. Radiotherapy potentiation with weekly cisplatin compared to standard every 3 weeks cisplatin chemotherapy for locoregionally advanced head and neck squamous cell carcinoma.
Fayette J; Molin Y; Lavergne E; Montbarbon X; Racadot S; Poupart M; Ramade A; Zrounba P; Ceruse P; Pommier P
Drug Des Devel Ther; 2015; 9():6203-10. PubMed ID: 26648696
[TBL] [Abstract][Full Text] [Related]
22. Hyperfractionated accelerated radiation therapy (HART) of 70.6 Gy with concurrent 5-FU/Mitomycin C is superior to HART of 77.6 Gy alone in locally advanced head and neck cancer: long-term results of the ARO 95-06 randomized phase III trial.
Budach V; Stromberger C; Poettgen C; Baumann M; Budach W; Grabenbauer G; Marnitz S; Olze H; Wernecke KD; Ghadjar P
Int J Radiat Oncol Biol Phys; 2015 Apr; 91(5):916-24. PubMed ID: 25670541
[TBL] [Abstract][Full Text] [Related]
23. Randomized trial comparing surgery and adjuvant radiotherapy versus concurrent chemoradiotherapy in patients with advanced, nonmetastatic squamous cell carcinoma of the head and neck: 10-year update and subset analysis.
Iyer NG; Tan DS; Tan VK; Wang W; Hwang J; Tan NC; Sivanandan R; Tan HK; Lim WT; Ang MK; Wee J; Soo KC; Tan EH
Cancer; 2015 May; 121(10):1599-607. PubMed ID: 25639864
[TBL] [Abstract][Full Text] [Related]
24. Mature results of a phase III randomized trial comparing concurrent chemoradiotherapy with radiation therapy alone in patients with stage III and IV squamous cell carcinoma of the head and neck.
Adelstein DJ; Lavertu P; Saxton JP; Secic M; Wood BG; Wanamaker JR; Eliachar I; Strome M; Larto MA
Cancer; 2000 Feb; 88(4):876-83. PubMed ID: 10679658
[TBL] [Abstract][Full Text] [Related]
25. Chemoradiotherapy with or without panitumumab in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-1): a randomised, controlled, open-label phase 2 trial.
Mesía R; Henke M; Fortin A; Minn H; Yunes Ancona AC; Cmelak A; Markowitz AB; Hotte SJ; Singh S; Chan AT; Merlano MC; Skladowski K; Zhang A; Oliner KS; VanderWalde A; Giralt J
Lancet Oncol; 2015 Feb; 16(2):208-20. PubMed ID: 25596660
[TBL] [Abstract][Full Text] [Related]
26. High-dose or low-dose cisplatin concurrent with radiotherapy in locally advanced head and neck squamous cell cancer.
Chang CL; Yuan KS; Wu SY
Head Neck; 2017 Jul; 39(7):1364-1370. PubMed ID: 28370614
[TBL] [Abstract][Full Text] [Related]
27. Panitumumab plus radiotherapy versus chemoradiotherapy in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-2): a randomised, controlled, open-label phase 2 trial.
Giralt J; Trigo J; Nuyts S; Ozsahin M; Skladowski K; Hatoum G; Daisne JF; Yunes Ancona AC; Cmelak A; Mesía R; Zhang A; Oliner KS; VanderWalde A
Lancet Oncol; 2015 Feb; 16(2):221-32. PubMed ID: 25596659
[TBL] [Abstract][Full Text] [Related]
28. Phase Ib study of duligotuzumab (MEHD7945A) plus cisplatin/5-fluorouracil or carboplatin/paclitaxel for first-line treatment of recurrent/metastatic squamous cell carcinoma of the head and neck.
Jimeno A; Machiels JP; Wirth L; Specenier P; Seiwert TY; Mardjuadi F; Wang X; Kapp AV; Royer-Joo S; Penuel E; McCall B; Pirzkall A; Clement PM
Cancer; 2016 Dec; 122(24):3803-3811. PubMed ID: 27525588
[TBL] [Abstract][Full Text] [Related]
29. Explaining Racial Disparities in Surgically Treated Head and Neck Cancer.
Jassal JS; Cramer JD
Laryngoscope; 2021 May; 131(5):1053-1059. PubMed ID: 33107610
[TBL] [Abstract][Full Text] [Related]
30. Effects of l-carnitine administration on health-related quality of life during cisplatin-based chemoradiotherapy in patients with head and neck squamous cell carcinoma.
Endo K; Ueno T; Ishikawa K; Nakanishi Y; Kondo S; Wakisaka N; Yoshizaki T
Auris Nasus Larynx; 2019 Jun; 46(3):431-436. PubMed ID: 30442437
[TBL] [Abstract][Full Text] [Related]
31. Postoperative Adjuvant Lapatinib and Concurrent Chemoradiotherapy Followed by Maintenance Lapatinib Monotherapy in High-Risk Patients With Resected Squamous Cell Carcinoma of the Head and Neck: A Phase III, Randomized, Double-Blind, Placebo-Controlled Study.
Harrington K; Temam S; Mehanna H; D'Cruz A; Jain M; D'Onofrio I; Manikhas G; Horvath Z; Sun Y; Dietzsch S; Dubinsky P; Holeckova P; El-Hariry I; Franklin N; Biswas-Baldwin N; Legenne P; Wissel P; Netherway T; Farrell J; Ellis C; Wang-Silvanto J; Amonkar M; Ahmed N; Santillana S; Bourhis J
J Clin Oncol; 2015 Dec; 33(35):4202-9. PubMed ID: 26527790
[TBL] [Abstract][Full Text] [Related]
32. Socioeconomic Status Drives Racial Disparities in HPV-negative Head and Neck Cancer Outcomes.
Lenze NR; Farquhar D; Sheth S; Zevallos JP; Blumberg J; Lumley C; Patel S; Hackman T; Weissler MC; Yarbrough WG; Zanation AM; Olshan AF
Laryngoscope; 2021 Jun; 131(6):1301-1309. PubMed ID: 33170518
[TBL] [Abstract][Full Text] [Related]
33. Quality of life scores as prognostic factors of overall survival in advanced head and neck cancer: analysis of a phase III randomized trial of pemetrexed plus cisplatin versus cisplatin monotherapy.
Urba S; Gatz J; Shen W; Hossain A; Winfree K; Koustenis A; Peterson P; Cohen EE
Oral Oncol; 2012 Aug; 48(8):723-9. PubMed ID: 22414289
[TBL] [Abstract][Full Text] [Related]
34. Phase 1 trial of bevacizumab with concurrent chemoradiation therapy for squamous cell carcinoma of the head and neck with exploratory functional imaging of tumor hypoxia, proliferation, and perfusion.
Nyflot MJ; Kruser TJ; Traynor AM; Khuntia D; Yang DT; Hartig GK; McCulloch TM; Wiederholt PA; Gentry LR; Hoang T; Jeraj R; Harari PM
Int J Radiat Oncol Biol Phys; 2015 Apr; 91(5):942-51. PubMed ID: 25659884
[TBL] [Abstract][Full Text] [Related]
35. Nutritional support dependence after curative chemoradiotherapy in head and neck cancer: supplementary analysis of a phase II trial (JCOG0706S1).
Imamura Y; Kiyota N; Ogawa G; Akimoto T; Fujii M; Hanai N; Iwae S; Monden N; Matsuura K; Onozawa Y; Hayashi R; Tahara M;
Jpn J Clin Oncol; 2019 Dec; 49(11):1009-1015. PubMed ID: 31665358
[TBL] [Abstract][Full Text] [Related]
36. Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer.
Hitt R; López-Pousa A; Martínez-Trufero J; Escrig V; Carles J; Rizo A; Isla D; Vega ME; Martí JL; Lobo F; Pastor P; Valentí V; Belón J; Sánchez MA; Chaib C; Pallarés C; Antón A; Cervantes A; Paz-Ares L; Cortés-Funes H
J Clin Oncol; 2005 Dec; 23(34):8636-45. PubMed ID: 16275937
[TBL] [Abstract][Full Text] [Related]
37. Quality of life following treatment with intra-arterial cisplatin with concurrent radiation and erlotinib for locally advanced head and neck cancer.
Cossyleon R; Robinson K; Delfino K; Robbins KT; Rao K
Support Care Cancer; 2024 Jan; 32(2):93. PubMed ID: 38193937
[TBL] [Abstract][Full Text] [Related]
38. Chemoradiation-induced hearing loss remains a major concern for head and neck cancer patients.
Schmitt NC; Page BR
Int J Audiol; 2018 Sep; 57(sup4):S49-S54. PubMed ID: 28728452
[TBL] [Abstract][Full Text] [Related]
39. Quality of Life of Patients with Squamous Cell Carcinoma of the Head and Neck Receiving High-Dose Cisplatin Chemotherapy and Radiotherapy.
Visacri MB; Ferrari GB; Dias P; Pimentel R; de Souza CM; Costa AP; de Carvalho Pincinato E; Lima CS; Mazzola PG; Moriel P
South Med J; 2015 Jun; 108(6):343-9. PubMed ID: 26079459
[TBL] [Abstract][Full Text] [Related]
40. A randomised phase II study of chemoradiotherapy with or without nimotuzumab in locally advanced oesophageal cancer: NICE trial.
de Castro Junior G; Segalla JG; de Azevedo SJ; Andrade CJ; Grabarz D; de Araújo Lima França B; Del Giglio A; Lazaretti NS; Álvares MN; Pedrini JL; Kussumoto C; de Matos Neto JN; Forones NM; Fernandes Júnior HJ; Borges G; Girotto G; da Silva IDCG; Maluf-Filho F; Skare NG
Eur J Cancer; 2018 Jan; 88():21-30. PubMed ID: 29179134
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]